Jochen Lorch, MD
Hematology & Oncology · Chicago, ILNPI 1518913094
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,659 of the $26,160 with a category attached, or 63.7%. 12 manufacturers reported payments, led by Novartis at 27.1% of the total. Reporting peaked in 2024 at $11,438 and has fallen 65.9% since, to $3,900 in 2025.
Across 33 payments — averaging $792.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$7K
- Bayer$6K
- Exelixis Inc.$4K
- Eisai Inc.$4K
- Coherus Oncology, Inc.$2K
- Janssen Scientific Affairs, LLC$2K
- plus $238 from 6 others
Across 61 payments — averaging $51,944 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.6M
- Takeda Pharmaceuticals U.S.A., Inc.$675K
- Eli Lilly$362K
- Exelixis Inc.$142K
- Astellas Pharma Global Development$82K
- Bayer$68K
- plus $209K from 5 others
What the payments were for
- Consulting fees$16,65964%
- Speaking & faculty fees$5,98523%
- Travel & lodging$2,4189%
- Food & beverage$1,0984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $7,102 |
| Bayer | 11 | $6,341 |
| Exelixis Inc. | 4 | $4,297 |
| Eisai Inc. | 2 | $4,121 |
| Coherus Oncology, Inc. | 3 | $2,298 |
| Janssen Scientific Affairs, LLC | 1 | $1,763 |
| SK Life Science, Inc. | 1 | $105 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Seagen Inc. | 1 | $25 |
| Morphosys, US Inc. | 1 | $23 |
| Merck | 1 | $20 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,160 in reported general payments places this provider in the 80th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levothyroxine Sodium | 37 | $453 |
| Prochlorperazine Maleate | 23 | $197 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chicago
- Michael BishopChicago$974K
- Jamile ShammoChicago$910K
- Young Kwang ChaeChicago$563K
- Irfan MirzaChicago$544K
- Marina GarassinoChicago$397K
- Chih-Yi LiaoChicago$317K
- Rita NandaChicago$286K
- Shuo MaChicago$280K
- Santosh SarafChicago$275K
- Peter RiedellChicago$273K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.